NR1I2 and cholestasis: With the in-depth study of the pathogenesis of cholestasis, some key therapeutic targets have been successively identified: farnesoid X receptor (FXR); peroxisome proliferator-activated receptor (PPAR) (Beuers et al., 2015), which is involved in the regulation of bile acid metabolism; and the pregnane X receptor (PXR) (Teng and Piquette-Miller, 2007), which is involved in the regulation of liver detoxification.